In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study

Editorial by Stefan Agewall published on the April Issue of European Heart Journal – Cardiovascular Pharmacotherapy

Anticoagulants
Cardiovascular Pharmacotherapy


European Heart Journal - Cardiovascular Pharmacotherapy, Volume 5, Issue 2, April 2019, Pages 70–79

Dr Camm et al. analysed XANTUS study data and assessed outcomes associated with non-recommended dosing and patient characteristics that may have impacted dose choice. In Europe, the approved rivaroxaban dose for stroke prevention in patients with atrial fibrillation is 20 mg o.d., with 15 mg o.d. recommended in patients with creatinine clearance (CrCl) of 15–49 mL/min. However, non-recommended doses are prescribed in real-world practice. Baseline characteristics and 1-year outcomes were compared in 4464/6784 patients. Multivariable analysis identified age, anaemia, congestive heart failure, diabetes mellitus, CrCl, lower body weight, atrial fibrillation type, and vascular disease as predictors of non-recommended dosing. The authors concluded that non-recommended rivaroxaban dosing was associated with less favourable outcomes. Again, the conclusion was that treatment quality and adherence to guidelines are important.

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.

References


Agewall S. Adherence to guidelines and registry data. Eur Heart J Cardiovasc Pharmacother  2017;3:183–184.

Raatikainen MJP, Penttilä T, Korhonen P, Mehtälä J, Lassila R, Lehto M. The quality of warfarin therapy and CHA2DS2-VASc score associate with the incidence of myocardial infarction and cardiovascular outcome in patients with atrial fibrillation: data from the nationwide FinWAF Registry. Eur Heart J Cardiovasc Pharmacother  2018;4:211–219.

Goto S, Merrill P, Wallentin L, Wojdyla DM, Hanna M, Avezum A, Easton JD, Harjola VP, Huber K, Lewis BS, Parkhomenko A, Zhu J, Granger CB, Lopes RD, Alexander JH. Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. Eur Heart J Cardiovasc Pharmacother  2018;4:75–81

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.